SIRT1 and cardiomyopathy: In general, the ability of SIRT1 to inhibit p38 MAPK/NF-κB pathways reduces the levels of other inflammatory cytokines in DOX-induced cardiomyopathy, such as IL-1β, IL-6, IL-17, and TNF-α (Guo et al., 2013).